Equities research analysts forecast that Crispr Therapeutics AG (NASDAQ:CRSP) will post earnings of $0.04 per share for the current fiscal quarter, according to Zacks Investment Research. Four analysts have made estimates for Crispr Therapeutics’ earnings, with the highest EPS estimate coming in at $0.07 and the lowest estimate coming in at $0.01. Crispr Therapeutics posted earnings per share of ($0.92) in the same quarter last year, which would suggest a positive year over year growth rate of 104.3%. The company is scheduled to report its next quarterly earnings results on Monday, February 24th.

According to Zacks, analysts expect that Crispr Therapeutics will report full-year earnings of $0.65 per share for the current financial year, with EPS estimates ranging from $0.59 to $0.71. For the next financial year, analysts forecast that the company will post earnings of ($4.68) per share, with EPS estimates ranging from ($5.38) to ($3.67). Zacks’ EPS averages are an average based on a survey of research analysts that that provide coverage for Crispr Therapeutics.

Crispr Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Monday, October 28th. The company reported $2.40 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.95) by $3.35. The firm had revenue of $211.93 million for the quarter, compared to analysts’ expectations of $6.32 million. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%.

Several equities analysts recently issued reports on the company. Roth Capital upped their price objective on Crispr Therapeutics from $65.00 to $100.00 in a research report on Tuesday, November 19th. BidaskClub raised Crispr Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 30th. TheStreet upgraded Crispr Therapeutics from a “d” rating to a “c” rating in a research note on Monday, October 28th. Chardan Capital reaffirmed a “buy” rating and set a $72.50 price target on shares of Crispr Therapeutics in a report on Monday, November 18th. Finally, Oppenheimer increased their price objective on Crispr Therapeutics from $65.00 to $80.00 and gave the company an “outperform” rating in a research report on Monday, November 25th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $69.54.

In other Crispr Therapeutics news, Director Pablo J. Cagnoni sold 7,500 shares of the stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $62.00, for a total value of $465,000.00. Following the transaction, the director now owns 7,500 shares of the company’s stock, valued at $465,000. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, President Rodger Novak sold 33,618 shares of the firm’s stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total value of $2,353,260.00. Following the completion of the transaction, the president now directly owns 33,618 shares in the company, valued at $2,353,260. The disclosure for this sale can be found here. In the last ninety days, insiders sold 56,118 shares of company stock valued at $3,620,760. 21.40% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CRSP. BSW Wealth Partners bought a new position in shares of Crispr Therapeutics in the 2nd quarter worth approximately $39,000. Balyasny Asset Management LLC bought a new position in Crispr Therapeutics in the second quarter worth approximately $5,165,000. BNP Paribas Arbitrage SA bought a new position in Crispr Therapeutics in the second quarter worth approximately $41,000. Bank of New York Mellon Corp boosted its stake in shares of Crispr Therapeutics by 116.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 33,091 shares of the company’s stock worth $1,559,000 after acquiring an additional 17,810 shares during the last quarter. Finally, ARK Investment Management LLC boosted its stake in shares of Crispr Therapeutics by 34.7% during the 2nd quarter. ARK Investment Management LLC now owns 2,724,349 shares of the company’s stock worth $128,317,000 after acquiring an additional 701,332 shares during the last quarter. 49.81% of the stock is owned by hedge funds and other institutional investors.

NASDAQ CRSP traded up $1.66 during mid-day trading on Monday, reaching $72.37. The stock had a trading volume of 892,934 shares, compared to its average volume of 703,877. Crispr Therapeutics has a 1 year low of $22.22 and a 1 year high of $74.00. The stock has a market cap of $4.00 billion, a PE ratio of -21.04 and a beta of 3.30. The company has a fifty day moving average price of $54.81 and a 200 day moving average price of $47.38. The company has a debt-to-equity ratio of 0.06, a current ratio of 8.32 and a quick ratio of 8.32.

Crispr Therapeutics Company Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Further Reading: Momentum Indicators

Get a free copy of the Zacks research report on Crispr Therapeutics (CRSP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Crispr Therapeutics (NASDAQ:CRSP)



Source link